Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Maintenance vs Interruption in GIST
NCT02260505Phase 3Completed
- Sponsor
- Centre Léon Bérard
- Start
- Dec 2014
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Disease Free Survival at 6 years. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02260505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260505.